Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

PURPOSE: Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described. METHODS: Patients who received anti–PD-1/PD-L1 monotherapy or in co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Naidoo, Jarushka, Wang, Xuan, Woo, Kaitlin M., Iyriboz, Tunc, Halpenny, Darragh, Cunningham, Jane, Chaft, Jamie E., Segal, Neil H., Callahan, Margaret K., Lesokhin, Alexander M., Rosenberg, Jonathan, Voss, Martin H., Rudin, Charles M., Rizvi, Hira, Hou, Xue, Rodriguez, Katherine, Albano, Melanie, Gordon, Ruth-Ann, Leduc, Charles, Rekhtman, Natasha, Harris, Bianca, Menzies, Alexander M., Guminski, Alexander D., Carlino, Matteo S., Kong, Benjamin Y., Wolchok, Jedd D., Postow, Michael A., Long, Georgina V., Hellmann, Matthew D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5559901/
https://ncbi.nlm.nih.gov/pubmed/27646942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.68.2005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados